1. Home
  2. COLL vs AVDL Comparison

COLL vs AVDL Comparison

Compare COLL & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COLL
  • AVDL
  • Stock Information
  • Founded
  • COLL 2002
  • AVDL 2015
  • Country
  • COLL United States
  • AVDL Ireland
  • Employees
  • COLL N/A
  • AVDL 188
  • Industry
  • COLL Biotechnology: Pharmaceutical Preparations
  • AVDL Biotechnology: Pharmaceutical Preparations
  • Sector
  • COLL Health Care
  • AVDL Health Care
  • Exchange
  • COLL Nasdaq
  • AVDL Nasdaq
  • Market Cap
  • COLL 958.8M
  • AVDL 900.2M
  • IPO Year
  • COLL 2015
  • AVDL 1996
  • Fundamental
  • Price
  • COLL $30.35
  • AVDL $8.93
  • Analyst Decision
  • COLL Strong Buy
  • AVDL Strong Buy
  • Analyst Count
  • COLL 4
  • AVDL 6
  • Target Price
  • COLL $43.75
  • AVDL $18.17
  • AVG Volume (30 Days)
  • COLL 283.6K
  • AVDL 1.7M
  • Earning Date
  • COLL 08-07-2025
  • AVDL 08-07-2025
  • Dividend Yield
  • COLL N/A
  • AVDL N/A
  • EPS Growth
  • COLL N/A
  • AVDL N/A
  • EPS
  • COLL 1.25
  • AVDL N/A
  • Revenue
  • COLL $664,283,000.00
  • AVDL $194,450,000.00
  • Revenue This Year
  • COLL $20.04
  • AVDL $56.88
  • Revenue Next Year
  • COLL $3.98
  • AVDL $29.81
  • P/E Ratio
  • COLL $24.19
  • AVDL N/A
  • Revenue Growth
  • COLL 17.17
  • AVDL 252.64
  • 52 Week Low
  • COLL $23.23
  • AVDL $6.38
  • 52 Week High
  • COLL $42.29
  • AVDL $17.30
  • Technical
  • Relative Strength Index (RSI)
  • COLL 54.25
  • AVDL 41.81
  • Support Level
  • COLL $29.28
  • AVDL $8.52
  • Resistance Level
  • COLL $30.83
  • AVDL $8.94
  • Average True Range (ATR)
  • COLL 0.75
  • AVDL 0.41
  • MACD
  • COLL -0.00
  • AVDL -0.11
  • Stochastic Oscillator
  • COLL 51.63
  • AVDL 25.98

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Share on Social Networks: